HCA Healthcare (HCA) is well-poised for growth due to growing patient volumes, acquisitions and adequate cash-generating abilities.
GSK (GSK) partners with WuXi Biologics to develop bi- & multi-specific T-cell engaging antibodies. GSK will have an exclusive license to develop and commercialize these candidates.
Moderna (MRNA) inks an agreement to acquire OriCiro for $85 million. The acquisition is expected to expand and boost Moderna's mRNA manufacturing capabilities.
The EMA validates BioMarin's (BMRN) label expansion filing for Voxzogo to treat children under two years with achondroplasia. BMRN submits a filing for using Voxzogo in children under five years.
AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.
We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.
Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.
Here is how Basilea Pharmaceutica AG (BPMUF) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.
uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.
Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.